Stock ONCOZ ONCOZENGE AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases OncoZenge AB

Equities

ONCOZ

SE0015504097

Market Closed - Nasdaq Stockholm
Other stock markets
 08:59:40 10/05/2024 pm IST 		5-day change 1st Jan Change
3.955 SEK +2.20% Intraday chart for OncoZenge AB +2.99% +27.99%
08/04 Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board CI
04/04 OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OncoZenge Appoints Anna Asplind as Phase 3 Program Manager
AQ
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs
AQ
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager
AQ
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board
AQ
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™
AQ
OncoZenge Explores Strategic Options for BupiZenge™ in China
AQ
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™
AQ
OncoZenge submits application for PRIME status in the EU
AQ
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel
AQ
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast
AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States
AQ
OncoZenge provides strategy update
AQ
The new formulation of OncoZenge's drug candidate BupiZenge™ is clean
AQ
OncoZenge initiates toxicity study and announces modification to the clinical plan
AQ
Moberg Pharma AB : Interim report January - March 2021
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCOZ Stock
  4. News OncoZenge AB
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW